$ENGN

H.C. Wainwright reiterated a Buy rating and $4.00 price target for Engene Holdings (NASDAQ:ENGN) after a webinar on detalimogene for non-muscle invasive bladder cancer. The stock is down 81% year-to-date but may be undervalued, with negative $104M levered free cash flow. Engene plans a pivotal-cohort update in Q4 2026 and potential FDA approval in 2027. Management also discussed preclinical data and a surfactant pre-rinse cohort. Citizens maintains a Market Perform rating.

Grossman William (Interim Chief Medical Officer) purchased 5,102 shares of enGene Therapeutics Inc. (ENGN) at $1.97 on 2026-09-22.

EnGene Therapeutics Inc. (ENGN) reported Q3 earnings of $32.50 million, or $0.47 per share, down from $28.99 million, or $0.57 per share, in the same period last year.

enGene Therapeutics reported Q3 2026 financial results, with $266.3M in cash and a net loss of $32.5M. The company plans to update key regulatory data, hold a pre-BLA meeting, and initiate a BLA submission for detalimogene in Q4 2026. It also announced a surfactant safety run-in clearance and a webinar on preclinical data. The company is well-capitalized to support BLA filing and precommercial readiness.

enGene Therapeutics Inc. reported a net loss of $32.5M for 3Q FY2026, an increase from $29M in the same period last year. Diluted loss per share was $0.47, an improvement from $0.57. The company had no product revenue. Clinical progress was noted in the LEGEND study, with a 54% any-time complete response rate. The company plans to submit a BLA in Q4 2026 and expects cash to last at least 12 months.

enGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 enGene Reports Third Quarter 2026 Financial Results and Provides Business Update Data update on key regulatory endpoints, complete response (CR) at any time and maturing durability, as well as landmark CR rates from LEGEND's pivotal cohort planned for 4Q 2026 Pre-Bio

Analyst estimates for enGene Therapeutics Inc. show its average 12-month price target was cut from $3.50 to $3.43, with a range of $2 to $5 per share. Based on the Aug. 14 close, the target implies about 102% upside. The consensus rating remains “Hold” with 4 Buys, 5 Holds, and 1 Sell.

enGene Therapeutics (Nasdaq: ENGN) announced board changes, with Michael Heffernan becoming Chairman and Dr. Richard Glickman stepping down. The company plans a 2H 2026 FDA Pre-BLA meeting and BLA submission for detalimogene, targeting potential FDA approval in 2027. Detalimogene is in Phase 2 LEGEND for high-risk BCG-unresponsive NMIBC.

enGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001980845 00-0000000 0001980845 us-gaap:CommonStockMember 2026-07-15 2026-07-15 0001980845 2026-07-15 2026-07-15 0001980845 us-gaap:WarrantMember 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursu

Biotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.